Complement-blocking peptide AMY-101 protects tissue in an NMOSD mouse model

What happened

A preclinical study tested AMY-101, a peptide inhibitor of complement component C3, in cell experiments and an intracerebral-injection mouse model of neuromyelitis optica spectrum disorder. NMOSD is an autoimmune inflammatory disease that commonly affects the optic nerves and spinal cord.

What the study found

AMY-101 reduced complement-mediated cell injury and membrane-attack-complex deposition in vitro. In mice, treatment was associated with less astrocyte loss, aquaporin-4 depletion and demyelination than untreated controls.

Evidence check

The model reproduces selected pathological features through a controlled experimental injury; it does not capture the full course, dosing environment or heterogeneity of human NMOSD. Mouse tissue protection cannot establish clinical benefit, route feasibility or long-term infection risk from complement inhibition.

Why it matters

Complement is already a clinically important pathway in NMOSD, and C3 sits upstream of several downstream effectors. A peptide inhibitor could offer a different intervention point, but the next questions are systemic pharmacology, safety and performance in more representative models before human efficacy can be discussed.